Prime Medicine, Inc. Common Stock (PRME) Stock Price

PRMEStock

$3.47−40.17%52W

Market Cap$629.38M

P/E—

PEG Ratio—

Div yield—

Beta2.31

PRME Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.12%

Price vs S&P 500 (4W)10.10%

VGM Score36.77

Book Value / Share (Quarterly)$0.22

P/TBV (Annual)2.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-16.96%

Cash Flow / Share (Quarterly)$-0.87

Price vs S&P 500 (YTD)-11.93%

Net Profit Margin (TTM)-4613.11%

EPS (TTM)$-1.09

10-Day Avg Trading Volume6.59M

EPS Excl Extra (TTM)$-1.09

EPS (Annual)$-1.35

ROI (Annual)-166.41%

Cash / Share (Quarterly)$0.53

Revenue Growth QoQ (YoY)3.50%

ROA (Last FY)-58.69%

Revenue Growth TTM (YoY)-17.90%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-110.15%

Operating Margin (TTM)-4824.94%

Cash Flow / Share (Annual)$-0.93

P/B Ratio15.81x

P/B Ratio (Quarterly)16.74x

Net Income / Employee (Annual)$-1,377,700

EV / Revenue (TTM)142.87x

Net Interest Coverage (TTM)-82.30x

ROA (TTM)-59.11%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)4.84x

Quick Ratio (Quarterly)3.01x

3-Month Avg Trading Volume3.64M

52-Week Price Return-40.17%

Revenue / Employee (TTM)$27,900

Tangible BV / Share (Quarterly)$1.99

P/S Ratio (Annual)135.88x

Asset Turnover (Annual)0.01x

52-Week High$6.56

EPS Excl Extra (Annual)$-1.35

CapEx CAGR (5Y)47.91%

26-Week Price Return-6.22%

Quick Ratio (Annual)4.76x

13-Week Price Return10.86%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.05x

Enterprise Value$581.93M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$31,700

Pretax Margin (Annual)-4342.44%

Cash / Share (Annual)$0.98

3-Month Return Std Dev92.79%

Net Income / Employee (TTM)$-1,286,900

ROE (Last FY)-166.41%

Net Interest Coverage (Annual)-25.03x

EPS Basic Excl Extra (Annual)$-1.35

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.09

ROI (TTM)-188.27%

P/S Ratio (TTM)154.52x

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$3.25

Price vs S&P 500 (52W)-55.70%

Year-to-Date Return0.00%

5-Day Price Return-3.88%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-63.07%

Net Profit Margin (Annual)-4342.44%

Month-to-Date Return13.58%

Cash Flow / Share (TTM)$-1.79

EBITD / Share (Annual)$-1.35

Operating Margin (Annual)-4498.06%

ROI (5Y Avg)-110.15%

EPS Basic Excl Extra (TTM)$-1.09

P/TBV (Quarterly)3.49x

P/B Ratio (Annual)5.18x

Pretax Margin (TTM)-4613.11%

Book Value / Share (Annual)$0.67

Price vs S&P 500 (13W)8.18%

Beta2.31x

Revenue / Share (TTM)$0.02

ROE (TTM)-188.27%

52-Week Low$2.67

vGradeF

gGradeD

mGradeB

vgmGradeD

PRME Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.26	-$0.24	+6.00%(+$0.02)
Q1 2026	May 7, 2026	-$0.25	-$0.28	-12.59%(-$0.03)
Q4 2025	Mar 3, 2026	-$0.26	-$0.24	+6.92%(+$0.02)
Q3 2025	Nov 7, 2025	-$0.25	-$0.32	-29.43%(-$0.07)
Q2 2025	Aug 7, 2025	-$0.34	-$0.41	-20.60%(-$0.07)

PRME Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.05

4.11

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PRMEPrime Medicine, Inc. Common Stock	F	D	B	154.5x	-17.9%	—	—	$3.47
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Prime Medicine, Inc. Common Stock

Prime Medicine Inc develops genetic therapies based on Prime Editing, a next-generation gene-editing technology designed to precisely correct genetic mutations and restore normal cellular function. The company targets rare and severe diseases with significant unmet medical needs across multiple therapeutic areas. Prime Editing's broader applicability compared to earlier gene-editing approaches positions the company to address a substantial market opportunity.